Seminars in Oncology
Volume 33, Issue 1 , Pages 86-97 , February 2006

Dermatologic Toxicity of Chemotherapeutic Agents

  • Aimee S. Payne

      Affiliations

    • Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, PA
    • Corresponding Author InformationAddress correspondence to Aimee S. Payne, MD, PhD, Department of Dermatology, University of Pennsylvania, 2 Rhoades Pavilion, 3600 Spruce St, Philadelphia, PA 19104
    • ,
  • William D. James

      Affiliations

    • Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, PA
    • ,
  • Raymond B. Weiss

      Affiliations

    • Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC

References 

  1. Susser WS , Whitaker-Worth DL , Grant-Kels JM . Mucocutaneous reactions to chemotherapy . J Am Acad Dermatol . 1999;40:367–398
  2. Asnis LA , Gaspari AA . Cutaneous reactions to recombinant cytokine therapy . J Am Acad Dermatol . 1995;33:393–410
  3. Remlinger KA . Cutaneous reactions to chemotherapy drugs (the art of consultation) . Arch Dermatol . 2003;139:77–81
  4. ten Bokkel Huinink WW , Prove AM , Piccart M , et al.   A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer . Ann Oncol . 1994;5:527–532
  5. Vanhooteghem O , Andre J , Vindevoghel A , et al.   Docetaxel-induced subungual hemorrhage . Dermatology . 1997;194:419–420
  6. Correia O , Azevedo C , Pinto-Ferreira E , et al.   Nail changes secondary to docetaxel (Taxotere) . Dermatology . 1999;198:288–290
  7. Vanhooteghem O , Richert B , Vindevoghel A , et al.   Subungual abscess (A new ungual side-effect related to docetaxel therapy) . Br J Dermatol . 2000;143:462–463
  8. Pavithran K , Doval DC . Nail changes due to docetaxel . Br J Dermatol . 2002;146:709–710
  9. Zimmerman GC , Keeling JH , Burris HA , et al.   Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent . Arch Dermatol . 1995;131:202–206
  10. Eich D , Scharffetter-Kochanek K , Eich HT , et al.   Acral erythrodysesthesia syndrome caused by intravenous infusion of docetaxel in breast cancer . Am J Clin Oncol . 2002;25:599–602
  11. Vukelja SJ , Lombardo FA , James WD , et al.   Pyridoxine for the palmar-plantar erythrodysesthesia syndrome . Ann Intern Med . 1989;111:688–689
  12. Vukelja SJ , Baker WJ , Burris HA , et al.   Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere . J Natl Cancer Inst . 1993;85:1432–1433
  13. Zimmerman GC , Keeling JH , Lowry M , et al.   Prevention of docetaxel-induced erythrodysesthesia with local hypothermia . J Natl Cancer Inst . 1994;86:557–558
  14. Scotté F , Tourani JM , Banu E , et al.   Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand . J Clin Oncol . 2005;23:4424–4429
  15. Young PC , Montemarano AD , Lee N , et al.   Hypersensitivity to paclitaxel manifested as a bullous fixed drug eruption . J Am Acad Dermatol . 1996;34:313–314
  16. Chu CY , Yang CH , Yang CY , et al.   Fixed erythrodysaesthesia plaque due to intravenous injection of docetaxel . Br J Dermatol . 2000;142:808–811
  17. Crowson A , Magro C . Recent advances in the pathology of cutaneous drug eruptions . Dermatol Clin . 1999;17:537–560
  18. Ozkaya-Bayazit E , Akar U . Fixed drug eruption induced by trimethoprim-sulfamethoxazole (Evidence for a link to HLA-A30 B13 Cw6 haplotype) . J Am Acad Dermatol . 2000;45:712–717
  19. Weiss RB , Donehower RC , Wiernik PH , et al.   Hypersensitivity reactions from taxol . J Clin Oncol . 1990;8:1263–1268
  20. Price KS , Castells MC . Taxol reactions . Allergy Asthma Proc . 2002;23:205–208
  21. ten Tije AJ , Verweij J , Loos WJ , et al.   Pharmacological effects of formulation vehicles (Implications for cancer chemotherapy) . Clin Pharmacokinet . 2003;42:665–685
  22. Laüchli S , Trüeb RM , Fehr M , et al.   Scleroderma-like drug reaction to paclitaxel (Taxol) . Br J Dermatol . 2002;147:619
  23. Cleveland MG , Ajaikumar BS , Reganti R . Cutaneous fibrosis induced by docetaxel (A case report) . Cancer . 2000;88:1078–1081
  24. Battafarano DF , Zimmerman GC , Older SA , et al.   Docetaxel (Taxotere) associated scleroderma-like changes of the lower extremities. A report of three cases . Cancer . 1995;76:110–115
  25. Chen M , Crowson AN , Woofter M , et al.   Docetaxel (taxotere) induced subacute cutaneous lupus erythematosus (Report of 4 cases) . J Rheumatol . 2004;31:818–820
  26. Berghammer P , Pohnl R , Baur M , et al.   Docetaxel extravasation . Support Care Cancer . 2001;9:131–134
  27. Shapiro J , Richardson GE . Paclitaxel-induced “recall” soft tissue injury occurring at the site of previous extravasation with subsequent intravenous treatment in a different limb . J Clin Oncol . 1994;12:2237–2238
  28. Meehan JL , Sporn JR . Case report of Taxol administration via central vein producing a recall reaction at a site of prior Taxol extravasation . J Natl Cancer Inst . 1994;86:1250–1251
  29. du Bois A , Kommoss FGM , Pfisterer J , et al.   Paclitaxel-induced “recall” soft tissue ulcerations occurring at the site of previous subcutaneous administration of paclitaxel in low doses . Gynecol Oncol . 1996;60:94–96
  30. Zulian GB , Aapro MS . Docetaxel and radiation-recall severe mucositis . Ann Oncol . 1994;5:964–966
  31. Raghavan VT , Bloomer WD , Merkel DE . Taxol and radiation recall dermatitis . Lancet . 1993;341:1354
  32. McCarty MJ , Peake MF , Lillis P , et al.   Paclitaxel-induced radiation recall dermatitis . Med Pediatr Oncol . 1996;27:185–186
  33. Yeo W , Leung SF , Johnson PJ . Radiation-recall dermatitis with docetaxel (Establishment of a requisite radiation threshold) . Eur J Cancer . 1997;33:698–699
  34. Tischler RB , Schiff PB , Geard CR , et al.   Taxol (A novel radiation sensitizer) . Int J Radiat Oncol Biol Phys . 1992;22:613–617
  35. Schrijvers D , van den Brande J , Vermorken JB . Supravenous discoloration of the skin due to docetaxel treatment . Br J Dermatol . 2000;142:1069–1070
  36. Hrushesky WJ . Serpentine supravenous fluorouracil hyperpigmentation . JAMA . 1976;236:138; (letter)
  37. Claudy AL , Levigne V , Boucheron S . Serpentine supravenous hyperpigmentation induced by the nitrosourea fotemustine . Dermatology . 1992;184:70–72
  38. Fine JD , Breathnach SM . Distinctive eruption characterized by linear supravenous papules and erythroderma following broxuridine (bromodeoxyuridine) therapy and radiotherapy . Arch Dermatol . 1986;122:199–200
  39. Cecchi R , Tuci F , Giomi A , et al.   Supravenous hyperpigmentation induced by vinorelbine . Dermatology . 1994;188:244
  40. Lang K , Groeger M , neumann NJ , et al.   Supravenous hyperpigmentation, transverse leuconychia and transverse melanonychia after chemotherapy for Hodgkin’s disease . J Eur Acad Dermatol Venereol . 2002;16:162–163
  41. Marcoux D , Anex R , Russo P . Persistent serpentine supravenous hyperpigmented eruption as an adverse reaction to chemotherapy combining actinomycin and vincristine . J Am Acad Dermatol . 2000;43:540–546
  42. Schulte-Huermann P , Zumdick M , Ruzicka T . Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma . Dermatology . 1995;191:65–67
  43. Pujol RM , Rocamora V , Lopez-Pousa A , et al.   Persistent supravenous erythematous eruption (A rare local complication of intravenous 5-fluorouracil therapy) . J Am Acad Dermatol . 1998;39:839–842
  44. Hrushesky WJ . Unusual pigmentary changes associated with 5-fluorouracil . Cutis . 1980;26:181–182
  45. Dourakis SP , Sevastianos VA , Alexopoulou A , et al.   Toxic, epidermal, necrolysis-like reaction associated with docetaxel chemotherapy . J Clin Oncol . 2002;20:3030–3032
  46. O’Brien ME , Wigler N , Inbar M , et al.   Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer . Ann Oncol . 2004;15:440–449
  47. Lotem M , Hubert A , Lyass O , et al.   Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin . Arch Dermatol . 2000;136:1475–1480
  48. Judson I , Radford JA , Harris M , et al.   Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma (A study by the EORTC Soft Tissue and Bone Sarcoma Group) . Eur J Cancer . 2001;37:870–877
  49. Lyass O , Uziely B , Ben-Yosef R , et al.   Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma . Cancer . 2000;89:1037–1047
  50. Kim RJ , Peterson G , Kulp B , et al.   Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers . Gynecol Oncol . 2005;97:374–378
  51. Lorusso D , Naldini A , Testa A , et al.   Phase II study of pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients. May a new treatment schedule improve toxicity profile? . Oncology . 2004;67:243–249
  52. Lopez AM , Wallace L , Dorr RT , et al.   Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia . Cancer Chemother Pharmacol . 1999;44:303–306
  53. Molpus KL , Anderson LB , Craig CL , et al.   The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma . Gynecol Oncol . 2004;93:513–516
  54. Hau P , Fabel K , Baumgart U , et al.   Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma . Cancer . 2004;100:1199–1207
  55. Vail DM , Chun R , Thamm DH , et al.   Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes (A randomized, double-blind clinical trial using a canine model) . Clin Cancer Res . 1998;4:1567–1571
  56. Skelton H , Linstrum J , Smith K . Host-vs.-altered-host eruptions in patients on liposomal doxorubicin . J Cutan Pathol . 2002;29:148–153
  57. English JC , Toney R , Patterson JW . Intertriginous epidermal dysmaturation from pegylated liposomal doxorubicin . J Cutan Pathol . 2003;30:591–595
  58. Markman M , Kulp B , Peterson G . Grade 3 liposomal-doxorubicin-induced skin toxicity in a patient following complete resolution of moderately severe sunburn . Gynecol Oncol . 2004;94:578–580
  59. Green MR . Gemcitabine safety overview . Semin Oncol . 1996;23:32–35
  60. Anderson H , Lund B , Bach F , et al.   Single-agent activity of weekly gemcitabine in advanced non-small cell lung cancer (A phase II study) . J Clin Oncol . 1994;12:1821–1826
  61. Kuku I , Kaya E , Sevinc A , et al.   Gemcitabine-induced erysipeloid skin lesions in a patient with malignant mesothelioma . J Eur Acad Dermatol Venereol . 2002;16:271–272
  62. Brandes A , Reichmann U , Plasswilm L , et al.   Time- and dose-limiting erysipeloid rash confined to areas of lymphedema following treatment with gemcitabine—A report of three cases . Anticancer Drugs . 2000;11:15–17
  63. Marucci G , Sgarbanti E , Maestri A , et al.   Gemcitabine-associated CD8+ CD30+ pseudolymphoma . Br J Dermatol . 2001;145:650–652
  64. Bessis D , Guillot B , Legouffe E , et al.   Gemcitabine-associated scleroderma-like changes of the lower extremities . J Am Acad Dermatol . 2004;51:73–76
  65. Chen GY , Chen YH , Hsu MML , et al.   Onychomadesis and onycholysis associated with capecitabine . Br J Dermatol . 2001;145:521
  66. Piguet V , Borradori L . Pyogenic granuloma-like lesions during capecitabine therapy . Br J Dermatol . 2002;147:1270–1272
  67. Lewis KG , Lewis MD , Robinson-Bostom L , et al.   Inflammation of actinic keratoses during capecitabine therapy . Arch Dermatol . 2004;140:367–368
  68. Burstein HJ . Radiation recall dermatitis from gemcitabine . J Clin Oncol . 2000;18:693–694
  69. Castellano D , Hitt R , Cortés-Funes H , et al.   Radiation recall reaction induced by gemcitabine . J Clin Oncol . 2000;18:695–696
  70. Jeter JD , Jänne PA , Brooks S , et al.   Gemcitabine-induced radiation recall . Int J Radiat Oncol Biol Phys . 2002;53:394–400
  71. Ortmann E , Hohenberg G . Radiation recall phenomenon after administration of capecitabine . J Clin Oncol . 2002;20:3029–3030
  72. Lawrence TS , Eisbruch A , Shewach DS . Gemcitabine-mediated radiosensitization . Semin Oncol . 1997;24:24–28
  73. Tich R . Capecitabine and radiation therapy for advanced gastrointestinal malignancies . Oncology . 2002;16:27–30
  74. Budman DR , Meropol NJ , Reigner B , et al.   Preliminary studies of a novel oral fluoropyrimidine carbamate (Capecitabine) . J Clin Oncol . 1998;16:1795–1802
  75. Dalbagni G , Russo P , Sheinfeld J , et al.   Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder . J Clin Oncol . 2002;20:3193–3198
  76. Park YH , Ryoo BY , Lee HJ , et al.   High incidence of severe hand-foot syndrome during capecitabine-docetaxel combination chemotherapy . Ann Oncol . 2003;14:1691–1692
  77. John W , Picus J , Blanke CD , et al.   Activity of multitargeted antifolate (pemextred disodium, LY231514) in patients with advanced colorectal carcinoma. Results from a phase II study . Cancer . 2000;88:1807–1813
  78. Clarke SJ , Abratt R , Goedhals L , et al.   Phase II trial of pemetrexed disodium (ALIMTA,LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer . Ann Oncol . 2002;13:737–741
  79. Martin M , Spielmann M , Namer M , et al.   Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines . Ann Oncol . 2003;14:1246–1252
  80. Cicchetti S , Jemec B , Gault DT . Two case reports of vinorelbine extravasation (management and review of the literature) . Tumori . 2000;86:289–292
  81. Hoff PM , Valero V , Ibrahim N , et al.   Hand-foot syndrome following prolonged infusion of high doses of vinorelbine . Cancer . 1998;82:965–969
  82. Verschraegen CF , Levy T , Kudelka AP , et al.   Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix . J Clin Oncol . 1997;15:625–631
  83. Nitschke R , Parkhurst J , Sullivan J , et al.   Topotecan in pediatric patients with recurrent and progressive solid tumors (A Pediatric Oncology Group phase II study) . J Pediatr Hematol Oncol . 1998;20:315–318
  84. Creemers GJ , Wanders J , Gamucci T , et al.   Topotecan in colorectal cancer (A phase II study of the EORTC early clinical trials group) . Ann Oncol . 1995;6:844–846
  85. Marini M , Wright D , Ropolo M , et al.   Neutrophilic eccrine hidradenitis secondary to topotecan . J Dermatol Treat . 2002;13:35–37
  86. Senturk N , Yanik F , Yildiz L , et al.   Topotecan-induced cellulitis-like fixed drug eruption . J Eur Acad Dermatol Venereol . 2002;16:411–427
  87. Perri AJ , Hsu S . A review of thalidomide’s history and current dermatological applications . Dermatol Online J . 2003;9:5
  88. Calabrese L , Fleischer AB . Thalidomide (Current and potential clinical applications) . Am J Med . 2000;108:487–495
  89. Hayashi T , Hideshima T , Anderson KC . Novel therapies for multiple myeloma . Br J Haematol . 2003;120:10–17
  90. Matthews SJ , McCoy C . Thalidomide (A review of approved and investigational uses) . Clin Therapeut . 2003;25:342–395
  91. Hall VC , El-Azhary RA , Bouwhuis S , et al.   Dermatologic side effects of thalidomide in patients with multiple myeloma . J Am Acad Dermatol . 2003;48:548–552
  92. Fine HA , Figg WD , Jaeckle K , et al.   A phase II trial of the anti-angiogenic agent, thalidomide, in patients with recurrent high-grade gliomas . J Clin Oncol . 2000;18:708–715
  93. Williams I , Weller IV , Malni A , et al.   Thalidomide hypersensitivity in AIDS . Lancet . 1991;337:436–437
  94. Bayard PJ , Berger TG , Jacobson MA . Drug hypersensitivity reactions and human immunodeficiency virus disease . J Acquir Immune Defic Syndr . 1992;5:1237–1257
  95. Wolkenstein P , Latarjet J , Roujeau JC , et al.   Randomized comparison of thalidomide versus placebo in toxic epidermal necrolysis . Lancet . 1998;352:1586–1589
  96. Rajkumar SV , Gertz MA , Witzig TE . Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma . N Engl J Med . 2000;343:972–973
  97. Lowndes S , Darby A , Mead G , et al.   Stevens-Johnson syndrome after treatment with rituximab . Ann Oncol . 2002;13:1948–1950
  98. Dillman RO . Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy . Cancer Metast Rev . 1999;18:465–471
  99. D’Arcy CA , Mannik M . Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab) . Arthritis Rheum . 2001;44:1717–1718
  100. Herishanu Y . Rituximab-induced serum sickness . Am J Hematol . 2002;70:329
  101. Grillo-Lopez AJ , White CA , Varns C , et al.   Overview of the clinical development of rituximab (First monoclonal antibody approved for the treatment of lymphoma) . Semin Oncol . 1999;26:66–73
  102. Druker BJ , Talpaz M , Resta DJ , et al.   Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia . N Engl J Med . 2001;344:1031–1037
  103. Druker BJ , Sawyers CL , Kantarjian H , et al.   Activity of a specific inhibitor of the bcr-abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome . N Engl J Med . 2001;344:1038–1042
  104. Joensuu H , Roberts PJ , Sarlomo-Rikala M , et al.   Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor . N Engl J Med . 2001;344:1052–1056
  105. Valeyrie L , Bastuji-Garin S , Revuz J , et al.   Adverse cutaneous reactions to imatinib (ST1571) in Philadelphia chromosome-positive leukemias (A prospective study of 54 patients) . J Am Acad Dermatol . 2003;48:201–206
  106. Hsiao LT , Chung HM , Lin JT , et al.   Stevens-Johnson syndrome after treatment with ST1571 (A case report) . Br J Haematol . 2001;117:620–622
  107. Rule SAJ , O’Brien SG , Crossman LC . Managing cutaneous reactions to imatinib therapy . Blood . 2002;100:3434–3435
  108. Milojkovic D , Short K , Salisbury JR , et al.   Dose-limiting dermatological toxicity secondary to imatinib mesylate (ST1571) in chronic myeloid leukaemia . Leukemia . 2003;17:1414–1416
  109. Tanvetyanon T . Overcoming recurrent cutaneous reactions from imatinib using once-weekly dosing . Ann Pharmacol . 2003;37:1818–1820
  110. Brouard MC , Prins C , Mach-Pascual S , et al.   Acute generalized exanthematous pustulosis associated with ST1571 in a patient with chronic myeloid leukemia . Dermatology . 2001;203:57–59
  111. Schwarz M , Kreuzer KA , Baskaynak G , et al.   Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia . Eur J Haematol . 2002;69:254–256
  112. Roujeau JC , Bioulac-Sage P , Bourseau C , et al.   Acute generalized exanthematous pustulosis. Analysis of 63 cases . Arch Dermatol . 1991;127:1333–1338
  113. Liu D , Seiter K , Mathews T , et al.   Sweet’s syndrome with CML cell infiltration of the skin in a patient with chronic-phase CML while taking imatinib mesylate . Leukemia Res . 2004;28(suppl):61–63 Supp
  114. Ayirookuzhi SJ , Ma L , Ramshesh P , et al.   Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia . Arch Dermatol . 2005;141:368–370
  115. Rousselot P , Larghero J , Raffoux E , et al.   Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate . Br J Haematol . 2003;120:1089–1096
  116. Leong KW , Lee TC , Goh AS . Imatinib mesylate causes hypopigmentation in the skin . Cancer . 2004;100:2486–2487
  117. Tsao AS , Kantarjian H , Cortes J , et al.   Imatinib mesylate causes hypopigmentation in the skin . Cancer . 2003;98:2483–2487
  118. Grichnik JM , Burch JA , Burchette J , et al.   The SCF/Kit pathway plays a critical role in the control of normal human melanocyte homeostasis . J Invest Dermatol . 1999;113:139–140
  119. Drummond A , Micallef-Eynaud P , Douglas WS , et al.   A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (ST1571, Glivec) . Br J Dermatol . 2003;120:907–915
  120. Baselga J , Pfister D , Cooper MR , et al.   Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin . J Clin Oncol . 2000;18:904–914
  121. Baselga J , Rischin D , Ranson M , et al.   Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types . J Clin Oncol . 2002;20:4292–4302
  122. Herbst RS , Maddox AM , Rothenberg ML , et al.   Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors (Results of a phase I trial) . J Clin Oncol . 2002;20:3815–3825
  123. Needle MN . Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody . Semin Oncol . 2002;29:55–60
  124. Lee MW , Seo CW , Kim SW , et al.   Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor . Acta Dermatol Venereol . 2004;84:23–26
  125. Jacot W , Bessis D , Jorda E , et al.   Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours . Br J Dermatol . 2004;151:238–241
  126. Busam KJ , Capodieci P , Motzer R , et al.   Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225 . Br J Dermatol . 2001;144:1169–1176
  127. Cunningham D , Humblet Y , Siena S , et al.   Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer . N Engl J Med . 2004;351:337–345
  128. Kimyai-Asadi A , Jih MH . Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors . Arch Dermatol . 2002;138:129–131
  129. van Doorn R , Kirtschig G , Scheffer E , et al.   Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor . Br J Dermatol . 2002;147:598–601
  130. Albanell J , Rojo F , Averbuch S , et al.   Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients (Histopathologic and molecular consequences of receptor inhibition) . J Clin Oncol . 2002;20:110–124
  131. Murillas R , Larcher F , Conti CJ , et al.   Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure . EMBO J . 1995;14:5216–5223
  132. Hansen LA , Alexander N , Hogan ME , et al.   Genetically null mice reveal a central role for epidermal growth factor receptor in the differentiation of the hair follicle and normal hair development . Am J Pathol . 1997;150:1959–1975
  133. Saltz L , Kies MS , Abbruzzese J , et al.   The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies . Proc Am Soc Clin Oncol . 2003;22:204; (abstr 817)
  134. Dainichi T , Tanaka M , Tsuruta N , et al.   Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inhibitor of epidermal growth factor receptor . Dermatology . 2003;207:324–325
  135. Trojan A , Jacky E , Follath F , et al.   Necrolytic migratory erythema (glucagonoma)-like skin lesions induced by EGF-receptor inhibition . Swiss Med Wkly . 2003;133:22–23
  136. Aghajanian C , Soignet S , Dizon DS , et al.   A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies . Clin Cancer Res . 2002;8:2505–2511
  137. Richardson PG , Barlogie B , Berenson J , et al.   A phase 2 study of bortezomib in relapsed, refractory myeloma . N Engl J Med . 2003;348:2609–2617
  138. Agterof MJ , Biesma DH . Images in clinical medicine. Bortezomib-induced skin lesions . N Engl J Med . 2005;352:2534

PII: S0093-7754(05)00434-3

doi: 10.1053/j.seminoncol.2005.11.004

Seminars in Oncology
Volume 33, Issue 1 , Pages 86-97 , February 2006

Article Tools

* Image Usage & Resolution